The Discovery and Preclinical Profile of ALG-000184, a Prodrug of the Potent Hepatitis B Virus Capsid Assembly Modulator ALG-001075

Abstract

Chronic hepatitis B (CHB) represents a significant unmet medical need with few options beyond lifelong treatment with nucleoside analogues, which rarely leads to a functional cure. Novel agents that reduce levels of HBV DNA, RNA and other viral antigens could lead to better treatment outcomes. The capsid assembly modulator (CAM) class of compounds represents an important modality for chronic suppression and to improve functional cure rates, either alone or in combination. <b>GLP-26</b> is a potent CAM, which in this work was optimized for potency, safety, and other drug-like properties leading to <b>ALG-001075</b>. <b>ALG-001075</b> was further advanced through clinical development as the highly soluble prodrug <b>ALG-000184</b>. <b>ALG-000184</b> is currently being explored in multiple clinical trials in HBV-infected subjects where unprecedented reductions in HBV DNA, RNA and other viral antigens have been observed, making <b>ALG-000184</b> a promising candidate to become a cornerstone for future chronic suppressive and combination treatment regimens for CHB.